ISTA seeks FDA OK for phase IIb trial

May 1, 2005

Irvine, CA—ISTA Pharmaceuticals is asking the FDA for permission to conduct a phase IIb clinical trial for ecabet sodium, a prescription eye drop for treating keratoconjunctivitis sicca (dry eye syndrome).

Irvine, CA-ISTA Pharmaceuticals is asking the FDA for permission to conduct a phase IIb clinical trial for ecabet sodium, a prescription eye drop for treating keratoconjunctivitis sicca (dry eye syndrome).

If the FDA approves ISTA's investigational new drug (IND) application, the company hopes to initiate the trial in the second quarter of 2005. The trial is designed to evaluate corneal and conjunctival staining and tear film break-up time, as well as any ocular symptoms, such as burning or stinging.